{"title":"Freedom of Exchange in Marketing versus Protection for Drug Consumers","authors":"R. A. Angorn","doi":"10.3109/J058V03N03_10","DOIUrl":null,"url":null,"abstract":"For many years critics in the popular press have periodically suggested that the FDA is overly aternalistic and inflexible and that the American public is ill-sewed g y the FDA's reluctance to make decisions. As a result, they claim, Americans are being denied drugs that are available to Europeans and the FDA is fostering a medical monopoly by restricting most drugs to rescri tion status. A , comparison was made of the pertinent laws o ! Cana c! a, Great Britain, Germany, and Third World, developing countries to see if there is a trend developing toward enactment of consumer protection legislation for drug roducts and the extent to which consumers are allowed or denied the freedom to purchase different categories of drugs.","PeriodicalId":16734,"journal":{"name":"Journal of Pharmaceutical Marketing & Management","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2011-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Marketing & Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/J058V03N03_10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
For many years critics in the popular press have periodically suggested that the FDA is overly aternalistic and inflexible and that the American public is ill-sewed g y the FDA's reluctance to make decisions. As a result, they claim, Americans are being denied drugs that are available to Europeans and the FDA is fostering a medical monopoly by restricting most drugs to rescri tion status. A , comparison was made of the pertinent laws o ! Cana c! a, Great Britain, Germany, and Third World, developing countries to see if there is a trend developing toward enactment of consumer protection legislation for drug roducts and the extent to which consumers are allowed or denied the freedom to purchase different categories of drugs.